If you are searching for a product that treats both the symptoms and the underlying degenerative disease process of horse's joint problems, Adequan i.m. Single Dose may be a good choice.
First, Adequan has important anti-inflammatory effects, so it is able to provide relief from the symptoms of joint damage: heat, swelling, pain and lameness. And Adequan can be found in synovial fluid at full herapeutic levels within only two hours of an intramuscular injection. Also, Adequan is a product with potent ability to block the action of the destructive enzymes that threaten to perpetuate the joint inflammation, attack the cartilage and break down synovial fluid.
Second, Adequan stimulates the synovial membrane to manufacture new, viscous synovial fluid to replace the thin fluid that was produced when the joint became injured. By improving this fluid, Adequan helps the joint regain its ability to lubricate and guard itself against further inflammation, and helps reestablish nutrition to the cartilage. And, Adequan attaches itself to damaged cartilage where it has a positive effect on cartilage metabolism. This should favor the cartilage repair process.
Adequan is the only joint treatment proven to reduce the inflammation and pain of degenerative joint disease, but also to help stop the degenerative process while stimulating the production of new joint fluid and new cartilage components. You are no longer just treating symptoms: you're doing something to help stop the degenerative process.
Adequan i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Polysulfated Glycosaminoglycan (PSGAG), 500 mg / 5 mL
The recommended dose of Adequan i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan i.m. with other drugs or solvents.
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.
The safe use of Adequan i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.
Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.
Store and 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Keep out of reach of children and animals. Discard unused portion. Dispose of spent needles in accordance with all federal, state, and local environmental laws.
As the only PSGAG joint prescription, Adequan i.m. has a mode of action that helps treat degenerative joint disease (DJD) in multiple ways to keep joints moving. It is proven to:
Ask your veterinarian if Adequan i.m. is the right choice for your horse